Stock Fundamentals

Cipla: Growing stronger

Nalinakanthi V | Updated on January 22, 2018 Published on September 05, 2015

6Cipla_c.eps

Acquisition of two US companies will help Cipla scale up its presence in this key market



Cipla last week signed a definitive agreement to acquire two US-based generic drug makers — InvaGen Pharmaceuticals Inc and Exelan Pharmaceuticals Inc — in which the promoters of Hyderabad-based Hetero Drugs hold majority stake.

This deal, once completed, should strengthen the former’s presence in the world’s largest pharma market — the US. With the combined operating profit margin of these two companies estimated to be higher than Cipla’s consolidated operating margin, the acquisitions should improve margins for the latter.

The deal should add about 4 per cent to Cipla’s consolidated profit. At ₹649, the stock trades at about 21 times its 2016-17 estimated earnings; this includes profit accretion from the deal.

The stock has corrected over 10 per cent in the past month making it attractive for investors from a two- to three-year investment horizon. Peers such as Lupin and Sun Pharma trade at about 25 times their estimated 2016-17 earnings.

Diversify product pipeline

The acquisitions, which will entail cash outflow of $550 million, will help Cipla scale up its presence in the US and boost revenues from this geography.

InvaGen and Exelan reported combined revenue of $225 million (about ₹1,500 crore) for the 12-month period ended June 2015. This is about 13 per cent of Cipla’s consolidated revenues in 2014-15. Besides geographical expansion, the acquisition will also help the company diversify its product offering across therapeutic categories.

InvaGen has a diversified pipeline of about 40 drugs used to treat ailments, such as cardio-vascular diseases, neurological disorders, diabetes and infections; the drugs have been approved by the US Food and Drug Administration.

Of these, 32 products are currently sold in the market. About 30 are currently pending approval and are likely be commercialised over the next four years.

InvaGen is the first generic filer for five products with a cumulative annual market size of $8 billion. The company should enjoy exclusive marketing right for six months; this can lift Cipla’s revenue over the next three years. The management expects the US to sharply increase contribution to 20 per cent of consolidated revenue in the near future.

Leg-up to profits

This should lift Cipla’s profitability, given the healthy operating profit margin in the US. Further, the current combined operating profit margin of InvaGen and Exelan is estimated to be 20.6 per cent for the 12-month period ended June 2015.

This is 1.6 percentage points higher than the 19 per cent operating margin reported by Cipla on consolidated basis in 2014-15. The acquisition should thus provide a leg up to Cipla’s blended operating profit margin.

Cipla will also gain access to a large capacity manufacturing base in Hauppauge, New York and R&D infrastructure in the US. This can be used by the company to file other products for the US market. This deal reinforces the company’s commitment to build its own front-end in key markets; it has now established front-end in 25 markets across Europe, Asia and Africa. These initiatives should help Cipla improve its profitability steadily over the next few years.

Cipla has been expanding operations in the domestic market too. As part of the pact with Serum Institute, Cipla has launched Nasovac, the first orally administered flu vaccine in India. Besides growing its traditional prescription business, the company’s consumer products division is also picking up.

Cipla’s consumer division launched its first product, Nicotex, a nicotine-based gum which helps smokers kick the habit. These should help sustain growth in the home market.

Cipla posted revenue growth of about 42 per cent in the June quarter, helped by supplies of generic esomeprazole to Teva for the US market. Its net profit more than doubled to ₹651 crore, compared with the same period last year.







Published on September 05, 2015

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Sincerely,

Support Quality Journalism
null
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.